

LifeMD, Inc. (LFMDP)

Nasdaq; healthcare; SIC 8011, Services-Offices & Clinics of Doctors of Medicine; CIK 0000948320

LifeMD, Inc. LFMDP; healthcare	
Grade	B A B C D E second fifth of 371 graded peers percentile 37.2; sampling error 2.5 points; lower is stronger
Rank	138 of 371
Profitability	C percentile 44.2
Solvency	D percentile 64.1
Growth and financing	B percentile 22.8
Reliability	0.83 AUC filers with \$12.5M to \$120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025
Peer failure rate	1.07% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	\$12.5M to \$120M assets total assets \$70.4M
Standard universe	inside revenue above \$1M and assets above \$10M
Warnings	late filer not computable: dilution, short runway, distress, fortress balance sheet
Inputs computable	8 of 14
Graded from	filings received through Mar 10, 2026 213 days before the rescan; latest periodic filing 10-Q received Aug 5, 2026
Last close	\$23.53 2026-09-09; market equity \$0
Price used in grade	None



B, the elk
second fifth of its sector; letters are fifths of the 371 graded peers


Share price, twelve months to the rescan
split-adjusted close; the letter is fixed at the rescan that set it



Rescans on file: A/B from Mar 21, 2025, B from Mar 21, 2026, B/C from Apr 21, 2026

Letter at every rescans

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only



Business, in the company's words

opening of Item 1 of the 10-K received Mar 10, 2026

is a patient-centric, direct-to-patient healthcare company providing a high-quality, cost-effective, and convenient way for patients to access virtual medical care and pharmacy services. We believe the traditional healthcare model requiring patients to visit a physician's office, travel to a retail pharmacy, and return for follow-up appointments or prescription refills is complex, inefficient,

and costly which can discourage individuals from seeking necessary medical care and medications. At the same time, the United States ("U.S.") continues to experience shortages in primary care key specialty areas.

The fourteen inputs


lower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 44.2						
Gross profitability		236.2%	32.2%	0.4	372	2025-12-31
Return on invested capital		not computable	9.3%			one or more required annual facts are missing
Accruals ratio		8.3%	(6.6%)	90.6	811	2025-12-31
Gross margin stability, five years		2.4 pts	2.8 pts	41.5	243	2025-12-31
Solvency, sleeve percentile 64.1						
Twelve-month failure probability		not computable	0.07%			firm-wide XBRL shares cannot be assigned to one ticker class
Altman Z double-prime		(9.85)	(0.31)	60.6	756	2025-12-31
Net debt to EBITDA		not computable	1.82x			one or more required annual facts are missing
Interest coverage		(5.64x)	(4.51x)	46.9	81	2025-12-31
Current ratio		1.25x	2.96x	84.8	839	2025-12-31
Growth and financing, sleeve percentile 22.8						
Revenue growth, three-year compound		17.7%	10.0%	34.9	415	2025-12-31
Free cash flow growth, three-year compound		not computable	10.9%			current FCF must be positive and base FCF must exceed \$100,000 pretax income must exceed the validity floor and imply a 0%-100% tax rate
Reinvestment rate		not computable	37.1%			
Asset growth, three years		40.0%	2.1%	10.6	704	2025-12-31
Net share issuance, one year		not computable	2.5%			firm-wide XBRL shares cannot be assigned to one ticker class

Warnings

1 of 7 checks triggered; none of them enters the letter

Check	Measured
Late filer	found 1 NT 10-K/Q filings in the last eight quarters



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
134	Ionis Pharmaceuticals Inc. (IONS)	35.9	B	
135	Biocryst Pharmaceuticals Inc. (BCRX)	36.2	B	fortress balance sheet
136	Tenet Healthcare Corp. (THC)	36.5	B	
137	Sanuwave Health, Inc. (SNWV)	36.8	B	
138	LifeMD, Inc. (LFMD)	37.2	B	late filer
139	LifeMD, Inc. (LFMDP) <	37.2	B	late filer
140	Collegium Pharmaceutical, Inc. (COLL)	37.6	B/C	fortress balance sheet
141	Sunshine Biopharma Inc. (SBFM)	38.0	B/C	late filer
142	Sunshine Biopharma Inc. (SBFMW)	38.0	B/C	late filer
143	Artivion, Inc. (AORT)	38.4	B/C	
144	Lakeland Industries Inc. (LAKE)	38.6	B/C	late filer, fortress balance sheet

What the price implies

at the 2026-09-09 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	6.7%	8.0%	49
Distance from 52-week high	(6.9%)	(31.4%)	90
EBIT to enterprise value	not computable	(1.5%)	
Free cash flow yield	not computable	(1.0%)	
Book value to price	not computable	0.28	
Sales to price	not computable	0.31	
Composite equity issuance, five years	not computable	20.3%	
Relative strength against the sector, log excess return	(0.15)	(0.14)	49

Diagnostics

not in the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	pass
Operating cash flow above zero	pass
Return on assets improved	pass
Operating cash flow exceeds net income	fail
Long-term leverage fell	fail
Current ratio improved	pass
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	fail

Cash, filings, liquidity	
Cash and equivalents	n/a
Operating cash flow, four quarters	n/a
Months of runway	not finite
Days since last periodic filing	65 (10-Q received Aug 5, 2026)
Median daily dollar volume, 63 sessions	\$30,485

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	\$166.3M	2025-12-31	2026-03-10	10-K	0001493152-26-009549
2	assets	us-gaap:Assets	\$70.4M	2025-12-31	2026-03-10	10-K	0001493152-26-009549
3	net income	us-gaap:NetIncomeLoss	\$14.4M	2025-12-31	2026-03-10	10-K	0001493152-26-009549
4	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$8.3M	2025-12-31	2026-03-10	10-K	0001493152-26-009549
5	assets	us-gaap:Assets	\$76.1M	2024-12-31	2026-03-10	10-K	0001493152-26-009549
6	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$194.1M	2025-12-31	2026-03-10	10-K	0001493152-26-009549
7	gross profit	us-gaap:GrossProfit	\$133.4M	2024-12-31	2026-03-10	10-K	0001493152-26-009549
8	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$154.8M	2024-12-31	2026-03-10	10-K	0001493152-26-009549
9	gross profit	us-gaap:GrossProfit	\$133.6M	2023-12-31	2025-03-11	10-K	0001493152-25-009790
10	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$152.5M	2023-12-31	2025-03-11	10-K	0001493152-25-009790
11	gross profit	us-gaap:GrossProfit	\$100.4M	2022-12-31	2024-03-11	10-K	0001493152-24-009581
12	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$119.0M	2022-12-31	2024-03-11	10-K	0001493152-24-009581
13	gross profit	us-gaap:GrossProfit	\$74.9M	2021-12-31	2023-03-22	10-K	0001493152-23-008560
14	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$92.9M	2021-12-31	2023-03-22	10-K	0001493152-23-008560
15	current assets	us-gaap:AssetsCurrent	\$51.8M	2025-12-31	2026-03-10	10-K	0001493152-26-009549
16	current liabilities	us-gaap:LiabilitiesCurrent	\$41.6M	2025-12-31	2026-03-10	10-K	0001493152-26-009549
17	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-\$228.6M	2025-12-31	2026-03-10	10-K	0001493152-26-009549
18	operating income	us-gaap:OperatingIncomeLoss	-\$7.7M	2025-12-31	2026-03-10	10-K	0001493152-26-009549
19	book equity	us-gaap:StockholdersEquity	\$23.2M	2025-12-31	2026-03-10	10-K	0001493152-26-009549
20	liabilities	us-gaap:Liabilities	\$47.3M	2025-12-31	2026-03-10	10-K	0001493152-26-009549
21	interest expense	us-gaap:InterestExpense	\$1.4M	2025-12-31	2026-03-10	10-K	0001493152-26-009549
22	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$1.9M	2025-12-31	2026-03-10	10-K	0001493152-26-009549
23	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$17.5M	2024-12-31	2026-03-10	10-K	0001493152-26-009549
24	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$1.5M	2024-12-31	2026-03-10	10-K	0001493152-26-009549
25	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$8.8M	2023-12-31	2025-03-11	10-K	0001493152-25-009790
26	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$203,814	2023-12-31	2025-03-11	10-K	0001493152-25-009790
27	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$22.9M	2022-12-31	2024-03-11	10-K	0001493152-24-009581
28	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$366,633	2022-12-31	2024-03-11	10-K	0001493152-24-009581
29	depreciation amortization	us-gaap:Depreciation	\$865,524	2025-12-31	2026-03-10	10-K	0001493152-26-009549
30	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterests	\$10.2M	2025-12-31	2026-03-10	10-K	0001493152-26-009549
31	income tax	us-gaap:IncomeTaxExpenseBenefit	\$45,721	2025-12-31	2026-03-10	10-K	0001493152-26-009549
32	current assets	us-gaap:AssetsCurrent	\$52.4M	2024-12-31	2026-03-10	10-K	0001493152-26-009549
33	current liabilities	us-gaap:LiabilitiesCurrent	\$67.4M	2024-12-31	2026-03-10	10-K	0001493152-26-009549
34	assets	us-gaap:Assets	\$58.5M	2023-12-31	2025-03-11	10-K	0001493152-25-009790
35	assets	us-gaap:Assets	\$25.7M	2022-12-31	2024-03-11	10-K	0001493152-24-009581